Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BXRX

Baudax Bio (BXRX) Stock Price, News & Analysis

About Baudax Bio Stock (NASDAQ:BXRX)

Advanced Chart

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.01
$3.47
Volume
310,872 shs
Average Volume
281,029 shs
Market Capitalization
$1.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive BXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BXRX Stock News Headlines

Baudax Bio Announces Corporate Update
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Why Is Baudax Bio (BXRX) Stock Up 75% Today?
See More Headlines

BXRX Stock Analysis - Frequently Asked Questions

Baudax Bio, Inc. (NASDAQ:BXRX) announced its quarterly earnings data on Wednesday, August, 16th. The company reported ($1.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.04) by $0.55.

Baudax Bio's stock reverse split on the morning of Wednesday, November 30th 2022.The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Baudax Bio investors own include Vanguard Dividend Appreciation ETF (VIG), Vanguard Total Stock Market ETF (VTI), iShares Russell 1000 Growth ETF (IWF), Schlumberger (SLB), ARK Innovation ETF (ARKK), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/16/2023
Today
8/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BXRX
CIK
1780097
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($9.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$58.79 million
Net Margins
N/A
Pretax Margin
-18,950.64%
Return on Equity
N/A
Return on Assets
-175.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.07
Quick Ratio
0.07

Sales & Book Value

Annual Sales
$1.27 million
Price / Sales
0.90
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($14.93) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
52,460,000
Free Float
52,408,000
Market Cap
$1.14 million
Optionable
Not Optionable
Beta
1.57

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:BXRX) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners